People are on the move, and so is TB
US CDC now requires IGRA tests for immigrant or refugee status applicants
Accurate and timely screening for TB infection is critical to protect migrants and the communities that welcome them. The WHO now recommends systematic TB testing and treatment for migrants originating from countries with a high burden of TB (2).
In addition, the US CDC requires that from October 1, 2024, all panel physicians must perform a US FDA- or WHO-approved interferon-gamma release assay (IGRA) instead of the tuberculin skin test (TST) on applicants from high-TB-burden countries (3). TB blood tests are also required for applicants from low-TB-burden countries who show signs or symptoms of TB infection.
Reduce the risk of active TB in migrants
QuantiFERON-TB Gold Plus provides accurate, single-visit TB infection testing.
TB in immigrants
As immigrants suffer disproportionately from TB, accurate and timely detection of TB in immigrants is critical to ending the global TB epidemic. The WHO recommends systematic TB testing and treatment for immigrants originating from countries with a high burden of TB (2).